Below are the most recent publications written about "Molecular Targeted Therapy" by people in Profiles.
-
Winthrop KL, Bathon J, Kerschbaumer A, Isaacs JD, Mease P, Gottenberg JE, Crow MK, Kay J, Crofford L, Baraliakos X, Bykerk V, Siebert S, Kloppenburg M, Aletaha D, McInnes IB, Huizinga T, Voll R, Gravallese EM, Breedveld FC, van Vollenhoven R, Smolen JS. Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024. Ann Rheum Dis. 2025 Jun; 84(6):927-936.
-
Avelino ARM, Pulipati S, Jamouss K, Bhardwaj PV. Updates in Treatment of HER2-positive Metastatic Breast Cancer. Curr Treat Options Oncol. 2024 Dec; 25(12):1471-1481.
-
Bhardwaj PV, Abdou Y. Navigating Treatment Pathways in Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies. J Clin Oncol. 2024 Dec; 42(34):4012-4017.
-
Leylek O, Honeywell ME, Lee MJ, Hemann MT, Ozcan G. Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy. Gastric Cancer. 2024 Nov; 27(6):1201-1219.
-
Huck DM, Buckley LF, Chandraker A, Blankstein R, Weber B. Targeting Pharmacotherapies for Inflammatory and Cardiorenal Endpoints in Kidney Disease. J Cardiovasc Pharmacol. 2024 06 01; 83(6):511-521.
-
Yaniv B, Tanenbaum B, Kazakova V, Patel SA. Translational insights into the genetics and immunobiology of relapsed/refractory follicular lymphoma. Leuk Res. 2024 Jul; 142:107519.
-
Delva C, Pearson TF, Harris JE. Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development. Cutis. 2024 Apr; 113(4):156-158.
-
Mittal K, Joshi M. FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape. Med. 2024 Mar 08; 5(3):176-178.
-
Lei B, Sleiman MM, Cheng Q, Tu Z, Zhu P, Goddard M, Martins PN, Langerude L, Nadig S, Tomlinson S, Atkinson C. In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
-
Lechner K, Mott S, Al-Saifi R, Knipfer L, Wirtz S, Atreya R, Vieth M, Rath T, Fraass T, Winter Z, August A, Luban J, Zimmermann VS, Weigmann B, Neurath MF. Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis. Gastroenterology. 2021 10; 161(4):1270-1287.e19.